Orbital radiotherapy for thyroid eye disease

Current Opinion in Ophthalmology

Volumn 23, Issue 5, 2012, Pages 427-432

  Dolman, Peter J ^a   Rath, Suryasnata ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

external beam radiotherapy; Graves' orbitopathy; thyroid eye disease

Indexed keywords

GLUCOCORTICOID; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; SELENIUM;

CORTICOSTEROID THERAPY; DECOMPRESSION SURGERY; DIPLOPIA; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DYSTHYROID OPTIC NEUROPATHY; ENDOCRINE OPHTHALMOPATHY; HUMAN; MONOTHERAPY; MORNING DOSAGE; ORBITAL RADIOTHERAPY; OUTCOME ASSESSMENT; PATIENT SAFETY; PATIENT SELECTION; PRIORITY JOURNAL; RADIATION DOSE; RADIOTHERAPY; REVIEW; SCORING SYSTEM; STRABISMUS; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; DECOMPRESSION, SURGICAL; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; ORBIT; ORBITAL DISEASES;

EID: 84865477281     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3283560b2b     Document Type: Review

References (47)

1. Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010; 36:726-738.
2. Dolman PJ. Evaluating Graves' orbitopathy. Best Pract Res Cl Endocrinol 2012; 26:229-248.
3. Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves' orbitopathy. N Engl J Med 2011; 364:1920-1931.
4. Khanna D, Chong KK, Afifiyan NF, et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 2010; 117:133-139.
5. Aktaran S, Akarsu E, Erbagci I, et al. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy. Int J Clin Pract 2007; 61:45-51.
6. Wakelkamp IM, Baldeschi L, Saeed P, et al. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? a randomized controlled trial. Clin Endocrinol (Oxf) 2005; 63:323-328. (Pubitemid 41233451)
7. Wiersinga WM. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab 2011; 96:2386-2394.
8. Smith TJ. Insulin-like growth factor-i regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev 2010; 62:199-236.
9. Grudzenski S, Raths A, Conrad S, et al. Inducible response required for repair of low-dose radiation damage in human fibroblasts. Proc Natl Acad Sci U S A 2010; 107:14205-14210.
10. Luis AM, de Lucas RH, Moron AH, et al. Radiation therapy for the treatment of benign vascular, skeletal and soft tissue diseases. Clin Trans Onc 2008; 10:334-346.
11. Beierwaltes WH. X-ray treatment of malignant exophthalmos: a report of 28 patients. J Clin Endocrinol 1953; 13:1090-1100.
12. Donaldson SS, Bagshaw MA, Kriss JP. Supervoltage radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 1973; 37:276-285.
13. Prummel MF, Mourits MP, Blank L, et al. Randomized double blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993; 342:949-954. (Pubitemid 23305498)
14. Kahaly GJ, Rosler HP, Pitz S, Hommel G. Low-versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 2000; 85:102-108. (Pubitemid 32268798)
15. Cockerham KP, Kennerdell JS. Does radiotherapy have a role in the management of thyroid orbitopathy? Br J Ophthalmol 2002; 86:102-104.
16. Nygaard B, Specht L. Transitory blindness after retrobulbar irradiation of Graves' ophthalmopathy [letter]. Lancet 1998; 351:725-726. (Pubitemid 28105347)
17. Marquez SD, Lum BL, McDougall IR, et al. Long-term results of irradiation for patients with Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys 2001; 102:1473-1476.
18. Marcocci C, Bartalena L, Rocchi R, et al. Long-termsafety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 2003; 88:3561-3566. (Pubitemid 37034495)
19. Kinyoun JL, Kalina RE, Brower SA, et al. Radiation retinopathy after orbital irradiation for Graves' ophthalmopathy. Arch Ophthalmol 1984; 102:1473-1476. (Pubitemid 14048634)
20. Wakelkamp IMMJ, Tan H, Saeed P, et al. Orbital irradiation for Graves' ophthalmopathy. Is it safe? A long-term follow-up study. Ophthalmology 2004; 111:1557-1562. (Pubitemid 39030812)
21. Gorman CA, Garrity JA, Fatourechi V, et al. The aftermath of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2002; 109:2100-2107. (Pubitemid 35222568)
22. Snijders-Keilholz A, De Keizer RJW, Goslings BM, et al. Probable risk of tumour induction after retro-orbital irradiation for Graves' ophthalmopathy. Radiother Oncol 1996; 38:69-71. (Pubitemid 26040269)
23. Nguyen NP, Krafft SP, Vos P, et al. Feasibility of tomotherapy for Graves' ophthalmopathy: dosimetry comparison with conventional radiotherapy. Strahlenther Onkol 2011; 187:568-574.
24. Aktaran S, Akarsu E, Erbagci I, et al. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy. Int J Clin Pract 2007; 61:45-51.
25. Le Moli R, Baldeschi L, Saeed P, et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid 2007; 17:357-362. (Pubitemid 46776141)
26. El Fassi D, Nielsen CH, Junker P, et al. Systemic adverse events following rituximab therapy in patients with Graves' disease. J Endocrinol Invest 2011; 34:163-167.
27. Mourits MP. Does radiotherapy have a role in the management of thyroid orbitopathy? Br J Ophthalmol 2002; 86:102-104.
28. Behbehani R, Sergott RC, Savino PJ. Orbital radiotherapy for thyroid-related orbitopathy. Curr opin ophthalmol 2004; 15:479-482. (Pubitemid 39564467)
29. Kazim M, Trokel S, Moore S. Treatment of acute Graves orbitopathy. Ophthalmol 1991; 98:1443-1448.
30. Kahaly GJ. Management of moderately severe Graves' orbitopathy in Graves' orbitopathy: a multidisciplinary approach. Questions and Answers. In: Wiersinga WM, Kahaly GJ, editors, Basel: Karger; 2010.
31. Abboud M, Arabi A, Salti I, et al. Outcome of thyroid associated ophthalmopathy treated by radiation therapy. Radiat Oncol 2011; 6:46-54.
32. Li Yim JF, Sandinha T, Kerr JM, et al. Low dose orbital radiotherapy for thyroid eye disease. Orbit 2011; 30:269-274.
33. Matthiesen C, Thompson JS, Thompson D, et al. The efficacy of radiation therapy in the treatment of Graves' orbitopathy. Int J Radiat Oncol Biol Phys 2012; 82:117-123.
34. Prummel MF, Mourits MP, Blank L, et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993; 342:949-954. (Pubitemid 23305498)
35. Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 2000; 355:1505-1509. (Pubitemid 30237357)
36. Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab 2004; 89:15-20. (Pubitemid 38183852)
37. Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmol 2001; 108:1523-1534. (Pubitemid 32808323)
38. Gerling J, Kommerell G, Henne K, et al. Retrobulbar irradiation for thyroidassociated orbitopathy: double-blind comparison between 2.4 and 16 Gy. Int J Radiat Oncol Biol Phys 2003; 55:182-189. (Pubitemid 36020358)
39. Cardoso CC, Giordani AJ, Wolosker AM, et al. Protracted hypofractionated radiotherapy for Graves' ophthalmopathy: a pilot study of clinical and radiologic response. Int J Radiat Oncol Biol Phys 2012; 82:1285-1291.
40. Ng CM, Yuen HK, Choi KL, et al. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study. Hong Kong Med J 2005; 11:322-330. (Pubitemid 41499549)
41. Bartalena L, Marcocci C, Chiovato L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrino Metab 1991; 56: 1139-1144.
42. Marcocci C, Bartalena L, Bogazzi F, et al. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest 1991; 14:853-860.
43. Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2008; 115:398-409.
44. Wei RL, Cheng JW, Cai JP. The use of orbital radiotherapy for Graves' ophthalmopathy: quantitative review of the evidence. Ophthalmologica 2008; 222:27-31.
45. Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, et al. Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab 2009; 94:2708-2716.
46. Dolman PJ, Rootman J. VISA classification for Graves' orbitopathy. Ophthal Plast Reconstr Surg 2006; 22:319-324.
47. Dolman PJ, Cahill K, Czyz CN, et al. Reliability of estimating ductions in thyroid eye disease: an International Thyroid Eye Disease Society Multicenter Study. Ophthalmology 2012 119:382-389.